{"id":78758,"date":"2026-09-04T16:01:28","date_gmt":"2026-09-04T08:01:28","guid":{"rendered":"https:\/\/flcube.com\/?p=78758"},"modified":"2026-09-04T16:01:29","modified_gmt":"2026-09-04T08:01:29","slug":"simceres-culevibart-wins-nmpa-approval-as-chinas-rsv-prevention-monoclonal-antibody-yingmule","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=78758","title":{"rendered":"Simcere\u2019s Culevibart Wins NMPA Approval as China\u2019s RSV Prevention Monoclonal Antibody Yingmule"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Simcere Pharmaceutical Group (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/2096:HKG\">HKG: 2096<\/a>)<\/strong> announced that <strong>Culevibart Injection (trade name: Yingmule)<\/strong>, a domestic <strong>Category 1 biological drug<\/strong> developed under its strategic cooperation with <strong>Reyoung (Shandong) Biopharmaceutical Co., Ltd.<\/strong>, has been approved for marketing in China by the <strong>National Medical Products Administration (NMPA)<\/strong>. The monoclonal antibody is indicated to prevent <strong>respiratory syncytial virus (RSV)<\/strong> lower respiratory tract infections in newborns and infants entering their first RSV epidemic season, positioning <strong>Simcere<\/strong> as an early mover in one of pediatric prevention\u2019s most sought-after categories.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td>Agency<\/td><td><strong>National Medical Products Administration (NMPA)<\/strong>, China<\/td><\/tr><tr><td>Approval Type<\/td><td>Marketing approval<\/td><\/tr><tr><td>Product<\/td><td><strong>Culevibart Injection (Yingmule)<\/strong>, domestic Category 1 biological drug<\/td><\/tr><tr><td>Indication<\/td><td>Prevention of RSV lower respiratory tract infections in newborns\/infants born at or after 35 weeks of gestational age entering or born during their first RSV epidemic season<\/td><\/tr><tr><td>Exclusions<\/td><td>Children with chronic lung disease, bronchopulmonary dysplasia (BPD) or clinically significant congenital respiratory abnormalities<\/td><\/tr><tr><td>Date<\/td><td>03 Sept 2026<\/td><\/tr><tr><td>Next Steps<\/td><td>Commercialization in China under Simcere\u2019s exclusive Greater China rights<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> <strong>Culevibart<\/strong>, a recombinant human <strong>IgG1\u03ba monoclonal antibody<\/strong><\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Provides <strong>passive immunity<\/strong> by targeting <strong>epitope II of the RSV F protein<\/strong>, blocking viral entry<\/li>\n\n\n\n<li><strong>Half-Life Extension:<\/strong> Fc segment engineering achieves an extended antibody half-life<\/li>\n\n\n\n<li><strong>Dosing Regimen:<\/strong> A <strong>single intramuscular injection<\/strong> delivers continuous protection covering the entire RSV epidemic season<\/li>\n\n\n\n<li><strong>Commercial Structure:<\/strong> On <strong>20 August 2026<\/strong>, <strong>Simcere<\/strong> entered a strategic cooperation with <strong>Reyoung Bio<\/strong>, obtaining the <strong>exclusive commercialization rights<\/strong> of culevibart in <strong>Greater China<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-evidence-pivotal-phase-iii-study\" class=\"wp-block-heading\">Clinical Evidence \u2013 Pivotal Phase III Study<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>150 Days Post-Dose<\/th><th>240 Days Post-Dose<\/th><\/tr><\/thead><tbody><tr><td>Efficacy against RSV LRTI requiring medical intervention (outpatient, emergency or hospitalization)<\/td><td><strong>85.32%<\/strong><\/td><td><strong>82.04%<\/strong><\/td><\/tr><tr><td>Efficacy against RSV infection-induced hospitalization<\/td><td><strong>83.27%<\/strong><\/td><td><strong>78.44%<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The pivotal Phase III data underpinning the approval demonstrate strong and durable efficacy: at <strong>150 days post-dose<\/strong>, culevibart showed <strong>85.32%<\/strong> efficacy against RSV-caused lower respiratory tract infections requiring medical intervention and <strong>83.27%<\/strong> efficacy against RSV infection-induced hospitalization. At <strong>240 days post-dose<\/strong>, efficacy remained at <strong>82.04%<\/strong> and <strong>78.44%<\/strong> respectively \u2014 supporting the single-dose, full-season protection profile central to the product\u2019s value proposition.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Large addressable population:<\/strong> Nearly all infants are exposed to RSV within their first years of life, and first-season protection via a single injection addresses a major unmet need in China\u2019s pediatric preventive market<\/li>\n\n\n\n<li><strong>Differentiated profile:<\/strong> Extended half-life enabling one-shot, full-season coverage offers a clear convenience and adherence advantage over shorter-lived passive immunization options<\/li>\n\n\n\n<li><strong>Commercial control:<\/strong> <strong>Simcere\u2019s<\/strong> exclusive Greater China rights (secured 20 August 2026) give the group full command of launch strategy, pricing and channel execution<\/li>\n\n\n\n<li><strong>Partnership validation:<\/strong> The approval validates the <strong>Simcere\u2013Reyoung Bio<\/strong> strategic cooperation model pairing discovery\/development with scaled commercialization capability<\/li>\n\n\n\n<li><strong>Category momentum:<\/strong> With RSV prevention becoming a global pediatric priority, <strong>Yingmule<\/strong> positions <strong>Simcere<\/strong> (HKG: 2096) among the first domestic players with an approved monoclonal antibody option in China<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements:<\/strong> This brief is for informational purposes only and does not constitute investment advice or an offer to buy or sell any security. Statements regarding commercialization plans, market potential and product uptake are forward-looking and subject to risks and uncertainties, including pricing and reimbursement outcomes, competitive developments and real-world adoption. Actual results may differ materially. Readers should conduct their own due diligence before making investment decisions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/2026090302394_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026090302394_c.\"><\/object><a id=\"wp-block-file--media-4dafdceb-e2f8-408b-b98b-7ce956759dfc\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/2026090302394_c.pdf\">2026090302394_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/2026090302394_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-4dafdceb-e2f8-408b-b98b-7ce956759dfc\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Simcere Pharmaceutical Group (HKG: 2096) announced that Culevibart Injection (trade name: Yingmule), a domestic Category&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[1099,15,4925,271],"class_list":["post-78758","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-hkg-2096","tag-product-approvals","tag-reyoung-biopharmaceutical","tag-simcere-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Simcere\u2019s Culevibart Wins NMPA Approval as China\u2019s RSV Prevention Monoclonal Antibody Yingmule - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Simcere Pharmaceutical Group (HKG: 2096) announced that Culevibart Injection (trade name: Yingmule), a domestic Category 1 biological drug developed under its strategic cooperation with Reyoung (Shandong) Biopharmaceutical Co., Ltd., has been approved for marketing in China by the National Medical Products Administration (NMPA). The monoclonal antibody is indicated to prevent respiratory syncytial virus (RSV) lower respiratory tract infections in newborns and infants entering their first RSV epidemic season, positioning Simcere as an early mover in one of pediatric prevention\u2019s most sought-after categories.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=78758\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Simcere\u2019s Culevibart Wins NMPA Approval as China\u2019s RSV Prevention Monoclonal Antibody Yingmule\" \/>\n<meta property=\"og:description\" content=\"Simcere Pharmaceutical Group (HKG: 2096) announced that Culevibart Injection (trade name: Yingmule), a domestic Category 1 biological drug developed under its strategic cooperation with Reyoung (Shandong) Biopharmaceutical Co., Ltd., has been approved for marketing in China by the National Medical Products Administration (NMPA). The monoclonal antibody is indicated to prevent respiratory syncytial virus (RSV) lower respiratory tract infections in newborns and infants entering their first RSV epidemic season, positioning Simcere as an early mover in one of pediatric prevention\u2019s most sought-after categories.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=78758\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-04T08:01:28+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-04T08:01:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78758#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78758\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Simcere\u2019s Culevibart Wins NMPA Approval as China\u2019s RSV Prevention Monoclonal Antibody Yingmule\",\"datePublished\":\"2026-09-04T08:01:28+00:00\",\"dateModified\":\"2026-09-04T08:01:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78758\"},\"wordCount\":534,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"HKG: 2096\",\"Product approvals\",\"Reyoung Biopharmaceutical\",\"Simcere Pharmaceutical\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=78758#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78758\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=78758\",\"name\":\"Simcere\u2019s Culevibart Wins NMPA Approval as China\u2019s RSV Prevention Monoclonal Antibody Yingmule - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-09-04T08:01:28+00:00\",\"dateModified\":\"2026-09-04T08:01:29+00:00\",\"description\":\"Simcere Pharmaceutical Group (HKG: 2096) announced that Culevibart Injection (trade name: Yingmule), a domestic Category 1 biological drug developed under its strategic cooperation with Reyoung (Shandong) Biopharmaceutical Co., Ltd., has been approved for marketing in China by the National Medical Products Administration (NMPA). The monoclonal antibody is indicated to prevent respiratory syncytial virus (RSV) lower respiratory tract infections in newborns and infants entering their first RSV epidemic season, positioning Simcere as an early mover in one of pediatric prevention\u2019s most sought-after categories.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78758#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=78758\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78758#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Simcere\u2019s Culevibart Wins NMPA Approval as China\u2019s RSV Prevention Monoclonal Antibody Yingmule\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Simcere\u2019s Culevibart Wins NMPA Approval as China\u2019s RSV Prevention Monoclonal Antibody Yingmule - Insight, China&#039;s Pharmaceutical Industry","description":"Simcere Pharmaceutical Group (HKG: 2096) announced that Culevibart Injection (trade name: Yingmule), a domestic Category 1 biological drug developed under its strategic cooperation with Reyoung (Shandong) Biopharmaceutical Co., Ltd., has been approved for marketing in China by the National Medical Products Administration (NMPA). The monoclonal antibody is indicated to prevent respiratory syncytial virus (RSV) lower respiratory tract infections in newborns and infants entering their first RSV epidemic season, positioning Simcere as an early mover in one of pediatric prevention\u2019s most sought-after categories.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=78758","og_locale":"en_US","og_type":"article","og_title":"Simcere\u2019s Culevibart Wins NMPA Approval as China\u2019s RSV Prevention Monoclonal Antibody Yingmule","og_description":"Simcere Pharmaceutical Group (HKG: 2096) announced that Culevibart Injection (trade name: Yingmule), a domestic Category 1 biological drug developed under its strategic cooperation with Reyoung (Shandong) Biopharmaceutical Co., Ltd., has been approved for marketing in China by the National Medical Products Administration (NMPA). The monoclonal antibody is indicated to prevent respiratory syncytial virus (RSV) lower respiratory tract infections in newborns and infants entering their first RSV epidemic season, positioning Simcere as an early mover in one of pediatric prevention\u2019s most sought-after categories.","og_url":"https:\/\/flcube.com\/?p=78758","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-09-04T08:01:28+00:00","article_modified_time":"2026-09-04T08:01:29+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=78758#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=78758"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Simcere\u2019s Culevibart Wins NMPA Approval as China\u2019s RSV Prevention Monoclonal Antibody Yingmule","datePublished":"2026-09-04T08:01:28+00:00","dateModified":"2026-09-04T08:01:29+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=78758"},"wordCount":534,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["HKG: 2096","Product approvals","Reyoung Biopharmaceutical","Simcere Pharmaceutical"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=78758#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=78758","url":"https:\/\/flcube.com\/?p=78758","name":"Simcere\u2019s Culevibart Wins NMPA Approval as China\u2019s RSV Prevention Monoclonal Antibody Yingmule - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-09-04T08:01:28+00:00","dateModified":"2026-09-04T08:01:29+00:00","description":"Simcere Pharmaceutical Group (HKG: 2096) announced that Culevibart Injection (trade name: Yingmule), a domestic Category 1 biological drug developed under its strategic cooperation with Reyoung (Shandong) Biopharmaceutical Co., Ltd., has been approved for marketing in China by the National Medical Products Administration (NMPA). The monoclonal antibody is indicated to prevent respiratory syncytial virus (RSV) lower respiratory tract infections in newborns and infants entering their first RSV epidemic season, positioning Simcere as an early mover in one of pediatric prevention\u2019s most sought-after categories.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=78758#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=78758"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=78758#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Simcere\u2019s Culevibart Wins NMPA Approval as China\u2019s RSV Prevention Monoclonal Antibody Yingmule"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/78758","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=78758"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/78758\/revisions"}],"predecessor-version":[{"id":78760,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/78758\/revisions\/78760"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=78758"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=78758"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=78758"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}